Skip to content

Development of a Novel Strategy to Analyze the Effect on Gait Using Transcutaneous Spinal Current Stimulation in Incomplete Spinal Cord Injured Patients

Design of tSCS Strategies to Promote Neural Plasticity and Improve Functional Outcomes During Rehabilitation of Locomotion

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07289191
Enrollment
10
Registered
2025-12-17
Start date
2021-01-01
Completion date
2026-02-01
Last updated
2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gait Disorders, Neurologic, Motor Function; Retardation, Non Invasive Spinal Stimulation, Spinal Cord Injuries, Stimulation Charecteristic

Brief summary

To determine whether the combination of non-invasive spinal cord stimulation together with gait rehabilitation reduces spasticity and facilitates recovery of lower limb motor strength and gait function in patients with incomplete SCI, as well as studying the underlying physiopathological changes following incomplete SCI and its modulation by non-invasive stimulation techniques.

Detailed description

Methodology: This task will involve the clinical and functional assessment of patients completing gait training with and without tSCS as defined in T4.2 to demonstrate the effects of tSCS and define the most favorable parameters. During this task, the assessments that will be completed will be defined by IG and then carried out according to the methodology that is set and agreed upon. Assessments will need to evaluate several factors: * The American Spinal Cord Injury Association Impairment Scale (ASIA) and the International Standards for Neurological Classification of Spinal Cord Injury (ISNSCI)38 will be used to determine level and severity of SCI and to evaluate sensory and motor deficit. * For gait outcome measures, 10 meters walking test (10MWT) and Walking Index for SCI (WISCI) II will be assessed. * For spasticity evaluation, Modified Ashworth modified score (MAS) will be used. * Neurophysiological studies may be included to study: 1) spinal cord excitability using F and H wave, 2) corticospinal conduction using transcraneal magnetic stimulation for MEP recording, and 3) muscle activity using surface EMG recording of lower limb muscles.

Interventions

DEVICEtranscutaneous spinal cord stimulation

This study consisted of: (i) baseline condition; and (ii) tSCS conditions: which consisted of 7 different combinations applied to different segments of the spinal cord in the randomized order: C5, L1, Coc1, C5+L1, C5+Coc1, L1+Coc1, C5+L1+Coc1 and than (iii) final condition: Individuals with SCI realized all clinical assessment after the last condition of tDCSs. We included the final control condition to ensure the reliability of our findings. Baseline, tSCSs, and final control conditions were conducted as part of three assessments: the 6MWT and MVC-QM and MVC-TA, Hmax/Mmax ratio.

Sponsors

Institut Guttmann
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Male or female more than 18 years old; * With a stable traumatic o nor traumatic incomplete motor cervical or thoracic SCI; * Time since SCI more than 6 months; * American Spinal Injury Association Impairment Scale (AIS)-D who could realize gait at least 6 meters with or without technical help; * Capacity for compression the nature of the study and signed informed consent.

Exclusion criteria

* Unstable medical condition (cancer, acute infections, etc.); * Severe spasticity (≥ 3 score on the Modified Ashworth scale (MAS)), * Peripheral nerve affectation; * Ulcers on the electrode applied area; * Intolerance of tSCS.

Design outcomes

Primary

MeasureTime frameDescription
6MWTBaseline, after 3 weeks, and 1 week follow-up6 METER WALKING TEST

Secondary

MeasureTime frameDescription
MVCBaseline, after 3 weeks, and 1 week follow-upMaximum voluntary contraction
Hmax\Max ratioBaseline, after 3 weeks, and 1 week follow-up

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026